Firefly Bio

Crossfire Oncology

This company develops kinase-targeting inhibitors, degraders and degrader-antibody conjugates to treat cancer patients.

Profound Bio

This clinical-stage biotechnology company develops antibody-drug conjugates and targeted therapies for patients with solid tumors and hematological malignancies.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

Biotheryx

The company develops protein degrader medicines for patients with cancer and inflammatory diseases.

Catena Bio

This biotechnology firm develops protein conjugation technology and multi-payload therapeutic conjugates for biopharmaceutical companies to treat oncology and autoimmune diseases.

Hummingbird Bioscience

This company develops antibody-based therapeutics and drug conjugates for patients with hard-to-treat cancers and autoimmune diseases.

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.

Promatix

Promatix develops antibody-drug conjugates for cancer treatment using a proprietary multi-omics platform to identify and target specific tumour markers.